Conference Reports

Madrid
28 September 2019 - 02 October 2019
Dallas, Texas, US
17 May 2019 - 22 May 2019
Geneva, Switzerland
10 April 2019 - 13 April 2019
San Diego, California, US
18 May 2018 - 23 May 2018
Geneva
11 April 2018 - 14 April 2018
Sydney
23 November 2017 - 26 November 2017
Milan, Italy
09 September 2017 - 13 September 2017
Kuala Lumpur, Malaysia
20 July 2017 - 23 July 2017
Geneva
05 May 2017 - 08 May 2017
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 19 Dec 2019

First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.

Pearl Toh, 03 Dec 2018
Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.